Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
20 studies found for:    S0802
Show Display Options
Rank Status Study
1 Unknown  Sterimar vs Saline Sprays in Nasal Surgical Aftercare - a Blinded, Randomised Trial
Condition: Nasal Surgery
Interventions: Drug: Sterimar Spray;   Drug: Generic homemade nasal saline spray (salt and water)
2 Active, not recruiting Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Extensive Stage Small Cell Lung Cancer;   Recurrent Small Cell Lung Cancer
Interventions: Biological: ziv-aflibercept;   Drug: topotecan hydrochloride
3 Recruiting Biomarkers of Bone Resorption in Metastatic Prostate Cancer
Condition: Metastatic Prostate Cancer
Intervention:
4 Completed A Pilot Study of the Effects of Isotretinoin on Cognition, Learning and Memory
Condition: Acne Vulgaris
Intervention: Drug: Isotretinoin
5 Completed Nuclear Magnetic Resonance Therapy in Knee Osteoarthrosis
Condition: Osteoarthrosis
Interventions: Device: MRI therapy;   Device: MRI therapy (off)
6 Recruiting Study of Oral Anthocyanins on Insulin Resistance
Condition: Type 2 Diabetes
Intervention: Dietary Supplement: Mirtoselect
7 Completed Osteocel® Plus in Anterior Cervical Discectomy and Fusion (ACDF)
Condition: Degenerative Disc Disease in Cervical Spine
Intervention: Biological: Biologic - Osteocel Plus
8 Terminated
Has Results
Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases)
Conditions: Type 2 Diabetes Mellitus;   Cardiovascular Disease
Interventions: Drug: Aliskiren;   Drug: Placebo
9 Unknown  Comparison of Pressure Support and Pressure Control Ventilation in Chronic Respiratory Failure
Conditions: COPD;   Chest Wall Disease;   Neuromuscular Disease;   Obesity Hypoventilation
Interventions: Other: Pressure support ventilation;   Other: Pressure control ventilation
10 Completed
Has Results
Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.
Condition: Cardiovascular Diseases
Interventions: Drug: Telmisartan;   Drug: Combination of Telmisartan and Ramipril;   Drug: Ramipril
11 Completed A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)
Condition: Schizophrenia
Interventions: Drug: bitopertin [RO4917838];   Drug: Placebo
12 Completed Effectiveness of the Pelican Instrument in Medical Care
Condition: Asthma
Interventions: Other: PELICAN Primary Care;   Other: PELICAN Secondary Care
13 Suspended Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis
Condition: Severe Sepsis
Interventions: Drug: Talactoferrin alfa;   Drug: Placebo
14 Completed Compact Closed System Versus Mounted Open System (COSMOS)
Condition: Catheterization, Peripheral
Interventions: Device: Open Intravenous System - Vasocan®;   Device: Closed Intravenous System - Nexiva®
15 Completed
Has Results
Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium;   Drug: placebo
16 Available Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008
Condition: Chronic Myeloid Leukemia
Intervention: Drug: bosutinib
17 Completed
Has Results
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate
Conditions: Atrial Fibrillation;   Stroke
Interventions: Drug: warfarin;   Drug: Dabigatran dose 1;   Drug: Dabigatran dose 2
18 Unknown  Consolidation PET-based and Donor-based After Salvage Therapy in Patients With Hodgkin Lymphoma in Relapse or Refractory
Condition: Hodgkin's Lymphoma
Interventions: Other: Patients with negative PET after salvage therapy;   Other: Patients with positive PET after salvage therapy
19 Recruiting Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors
Condition: Gynecologic Tumors
Interventions: Drug: Oral Topotecan;   Drug: Pazopanib
20 Terminated Proton Therapy With Chemotherapy for Stage III Non-Small Cell Lung Cancer (LU02)
Condition: Non-Small Cell Lung Cancer
Interventions: Radiation: PET positive nodal disease measuring 15 mm or greater;   Radiation: PET positive nodal disease measuring less than 15 mm;   Radiation: Patients considered resectable

Indicates status has not been verified in more than two years